[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369765-105":59,"doc-detail-369765-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","computationally-accelerated-identification-of-p-glycoprotein-inhibitors","Computationally accelerated identification of P-glycoprotein inhibitors","","The work develops an enhanced computationally accelerated drug discovery pipeline to identify P-glycoprotein (P-gp) inhibitors, addressing multidrug resistance in cancer. P-gp overexpression drives MDR by acting as an ATP-powered efflux pump that lowers intracellular concentrations of chemotherapeutics, and many prior inhibitors fail due to poor clinical performance and binding/transport behaviors. Building on earlier evidence that P-gp nucleotide binding domains are viable targets, the study iteratively docks compounds against multiple P-gp conformations generated using targeted molecular dynamics and homology modeling. Custom Tanimoto chemical datasets expand ligand chemical diversity. The pipeline identifies nine novel P-gp inhibitors with a 13.4% hit rate, reversing MDR in two P-gp-overexpressing human cancer cell lines, showing non-toxicity in non-cancerous human cells, and suggesting six are unlikely to be transport substrates. Results support nucleotide binding domains as an underappreciated target for reversing P-gp-mediated MDR.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/computationally-accelerated-identification-of-p-glycoprotein-inhibitors/369765/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/computationally-accelerated-identification-of-p-glycoprotein-inhibitors/369765.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biological problem does this study address?","Question",{"text":112,"@type":113},"The study addresses multidrug resistance in cancer caused by overexpression of P-glycoprotein (P-gp), an ATP-powered efflux pump that reduces chemotherapeutic effectiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why focus on P-gp nucleotide binding domains?",{"text":117,"@type":113},"Prior work provided evidence that P-gp nucleotide binding domains are viable targets. This study builds on that by designing an accelerated pipeline targeting these domains.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the computational pipeline identify candidate inhibitors?",{"text":121,"@type":113},"It iteratively screens compounds by docking against multiple P-gp conformations generated through targeted molecular dynamics, while using custom Tanimoto chemical datasets to maximize chemical diversity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369765,1790253110,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","OPEN ACCESS  \nCitation: McCormick LA, McCormick JW, Park C, Follit CA, Wise JG, Vogel PD (2025) Computationally accelerated identification of P-glycoprotein inhibitors. PLoS One 20(8):  \ne0325121. [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0325121  \nEditor: Qiu Sun, Sichuan University West China Hospital, CHINA  \nReceived: June 14, 2024  \nAccepted: May 7, 2025  \nPublished: August 13, 2025  \nCopyright: © 2025 McCormick et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the paper and its Supporting  Information files.  \nFunding: This work was financially supported by the National Institutes of Health's (NIH) National Institute of General Medical Sciences (NIGMS) ([https://www.nigms.nih.gov](https://www.nigms.nih.gov)) in  \nRESEARCH ARTICLE  \nComputationally accelerated identification of P-glycoprotein inhibitors  \nLauren A. McCormick1,2,3☯, James W. McCormick1,2,3☯, Chanyang Park1,2,3, Courtney A. Follit1,2, John G. Wise1,2,3, Pia D. Vogel1,2*  \n1 Department of Biological Sciences, Southern Methodist University, Dallas, Texas, United States of America, 2 Center for Drug Discovery, Design and Delivery, Southern Methodist University, Dallas, Texas, United States of America, 3 Center for Scientific Computation, Southern Methodist University, Dallas, Texas, United States of America  \n☯ These authors contributed equally to this work.  \n* [pvogel@smu.edu](pvogel@smu.edu)  \nAbstract  \nOverexpression of the polyspecific efflux transporter, P-glycoprotein (P-gp, MDR1, ABCB1), is a major mechanism by which cancer cells acquire multidrug resistance (MDR), the resistance to diverse chemotherapeutic drugs. Inhibiting drug transport by P-gp can resensitize cancer cells to chemotherapy, but there are no P-gp inhibitors available to patients. Clinically unsuccessful P-gp inhibitors tend to bind at the pump’s transmembrane drug binding domains and are often P-gp transport substrates, resulting in lowered intracellular concentration of the drug and altered pharmacokinetics. In prior work, we used computationally accelerated drug discovery to identify novel P-gp inhibitors that target the pump’s cytoplasmic nucleotide binding domains. Our first-draft study provided conclusive evidence that the nucleotide binding domains of P-gp are viable targets for drug discovery. Here we develop an enhanced, computationally accelerated drug discovery pipeline that expands upon our prior work by iteratively screening compounds against multiple conformations of P-gp with molecular docking. Targeted molecular dynamics simulations with our homology model of human P-gp were used to generate docking receptors in conformations mimicking a putative drug transport cycle. We offset the increased computational complexity using custom Tanimoto chemical datasets, which maximize the chemical diversity of ligands screened by docking. Using our expanded, virtual-assisted pipeline, we identified nine novel P-gp inhibitors that reverse MDR in two types of P-gp overexpressing human cancer cell lines, reflecting a 13.4% hit rate. Of these inhibitors, all were non-toxic to non-cancerous human cells, and six were not likely to be transport substrates of P-gp. Our novel P-gp inhibitors are chemically diverse and are good candidates for lead optimization. Our results demonstrate that the nucleotide binding domains of P-gp are an underappreciated target in the effort to reverse P-gp-mediated multidrug resistance in cancer.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0325121](https://doi.org/10.1371/journal.pone.0325121) August 13, 2025 1 / 24  \nthe form of a grant (1R15GM094771-01A1) received by JGW and PDV. No additional external funding was received for this study.  \nCompeting interests: The authors ","cbCaibCRPNYIZdR3","https://ap.wps.com/l/cbCaibCRPNYIZdR3","pdf",1498195,24,"English","# Abstract\n# Introduction\n## Multidrug resistance and ATP-binding cassette transporters\n## P-glycoprotein structure and function\n## Prior generations of P-gp inhibitors","[{\"question\":\"What biological problem does this study address?\",\"answer\":\"The study addresses multidrug resistance in cancer caused by overexpression of P-glycoprotein (P-gp), an ATP-powered efflux pump that reduces chemotherapeutic effectiveness.\"},{\"question\":\"Why focus on P-gp nucleotide binding domains?\",\"answer\":\"Prior work provided evidence that P-gp nucleotide binding domains are viable targets. This study builds on that by designing an accelerated pipeline targeting these domains.\"},{\"question\":\"How does the computational pipeline identify candidate inhibitors?\",\"answer\":\"It iteratively screens compounds by docking against multiple P-gp conformations generated through targeted molecular dynamics, while using custom Tanimoto chemical datasets to maximize chemical diversity.\"}]","Computationally accelerated identification of P-glycoprotein inhibitors | PDF",1790184415,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f981a0a72fb0b0b29a93f91893a1d43.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/237948c35f0ddbe3f296cfbf592674bf.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b891ae06b3dc0b0ae61715287e9b798.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f1c41d9de4660bc9f41e13f61127d91.webp",980,1268]